PT - JOURNAL ARTICLE AU - D'Amours, Marie-Frédérique AU - Wu, Florence T.H. AU - Theisen-Lauk, Olivia AU - Chan, Elisa K. AU - McGuire, Anna AU - Ho, Cheryl TI - Surgically Resectable Non-Small Cell Lung Cancer: A Contemporary Approach AID - 10.1183/13993003.00332-2024 DP - 2024 Jan 01 TA - European Respiratory Journal PG - 2400332 4099 - https://publications.ersnet.org//content/early/2024/05/29/13993003.00332-2024.short 4100 - https://publications.ersnet.org//content/early/2024/05/29/13993003.00332-2024.full AB - New treatment paradigms for resectable non-small cell lung cancer (NSCLC), with an emphasis on personalized care and a multidisciplinary approach, have significantly improved patient outcomes. The incorporation of immune checkpoint inhibitors into neoadjuvant, perioperative and adjuvant treatment algorithms is reshaping the standard of care for resectable NSCLC. Adjuvant targeted therapy trials have also paved the way for a much-needed personalized approach for patients with actionable genomic alterations. Innovative surgical techniques and judicious use of post operative radiotherapy may mitigate the toxicity associated with a multimodality approach. Amidst many new treatment options, questions remain about the best approach to consider for each patient. Measurement of minimal residual disease and achievement of pathologic complete response are emerging biomarkers of interest to help further refine treatment selection. This review summarizes the current management of resectable NSCLC, focusing on ongoing and recent advances in surgical approaches, the role of postoperative radiotherapy, and the rapidly changing field of systemic therapies.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflicts of interest: Dr Marie-Frédérique D'Amours, Dr Elisa Chan and Dr Olivia Theisen-Lauk declare no potential conflict of interest.Conflicts of interest: Dr Cheryl Ho has received research grants from Astra Zeneca and Roche and honoraria for advisory boards from Abbvie, Amgen, Astra Zeneca, Bayer, BMS, Eisai, EMD Serono, Janssen, Jazz, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda.Conflicts of interest: Dr Florence T.H. Wu has received honoraria for an educational presentation from Bristol Myers Squibb.Conflicts of interest: Dr Anna McGuire has received an educational grant from Johnson & Johnson and honoraria for advisory boards from Astra Zeneca, Bristol Myers Squibb and Medtronic.